Invitrogen Corp. has announced the formation of a Flow Cytometry Scientific Advisory Board to be chaired by Dr. Leonard A. Herzenberg. Dr. Leonore A. Herzenberg will join the board as a member.
Together the two Stanford professors will help guide Invitrogen's efforts to bring its many product lines to bear on immunology, flow cytometry and cell biology.
170,000 life science researchers worldwide now use the technique of flow cytometry, making it a cornerstone of immunology and other research areas such as cell signaling, viability and apoptosis.
Additionally, it has been utilized for clinical diagnosis of leukemia/lymphoma and monitoring of HIV/AIDS disease and treatment progress.
In the late 1960s, Len Herzenberg invented the Fluorescent Activated Cell Sorter which introduced now essential methods for isolating and studying individual living cells.
He and Dr. Lee Herzenberg have continued to pioneer developments in flow cytometry, and new ways of using this technology in basic and applied medical science, including recently, knowledge-based software systems, which make the design and analysis of flow cytometry experiments widely accessible.
"Our connection to these pioneers of cell biology is vastly important as we expand our enabling technologies to new areas of medicine," explained John "Kip" Miller, Invitrogen's Senior Vice President, Enabling Technologies.
"Their guidance will help us transform a number of our separate product areas into a system for immunology and continues our company's pursuit of solutions that span the continuum of scientific discovery. We are honored to have them help with our efforts."
Invitrogen has a broad range of technologies for cellular labeling, isolation and analysis including its Molecular Probes line of labels and dyes, Quantum Dot semiconductor nanocrystals, and Dynabeads from its Dynal business.
Additionally, the company, through its acquisition of Caltag Laboratories, offers a collection of antibodies and reagents for immunology and the development of multi-color assays for flow cytometry.
"Invitrogen has a long history of developing technologies to advance research in the life sciences," said Len Herzenberg.
"As the company's efforts move toward patient-directed disciplines such as immunology, we hope to help integrate several applicable areas to improve and expand the practice of flow cytometry in medicine."
As a part of the collaboration, the Herzenbergs will help establish an Invitrogen Scientific Advisory Board for immunology and flow cytometry, and design and endorse educational materials and courses to expand the usage of flow cytometry.